A narrative literature review on the clinical utility of activated partial thromboplastin time and anti-factor Xa activity assays in cancer patients with anticoagulant therapy.

ABSTRACT:

Background and objective

Cancer patients face a substantially increased risk of venous thromboembolism (VTE), a leading cause of non-cancer mortality. Optimizing anticoagulation therapy in this population necessitates balancing thromboprophylaxis efficacy with hemorrhage risk, which is particularly challenging given comorbidities, polypharmacy, and tumor-specific factors such as gastrointestinal/urogenital malignancies amplifying bleeding risks with direct oral anticoagulants (DOACs). Monitoring anticoagulant activity is crucial to avoid subtherapeutic dosing or supratherapeutic dosing. This article provides a narrative review of the clinical utility of activated partial thromboplastin time (aPTT) and anti-factor Xa (anti-Xa) activity assays in anticoagulant therapy for cancer pati

SUBMITTER: Li HX 

PROVIDER: S-EPMC12605607 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature